BIOCORP and Théa Sign a Partnership for the Development of Innovative Digital Solutions
19 Giugno 2020 - 7:30AM
Business Wire
- BIOCORP will design and produce unique ophthalmic devices
accompanied by complete technological solutions.
- This new platform will aim at improving the compliance and
quality of life for patients and healthcare professionals.
Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME), a French
company specialized in the development and manufacturing of medical
devices and smart drug delivery systems, announces today the
signature of a partnership agreement with Théa, the European leader
in the field of ophthalmology.
Under this agreement, BIOCORP and Thea Laboratories (through
Thea Open Innovation) are joining forces to design, develop and
manufacture connected medical devices to help patients suffering
from blinding diseases such as glaucoma. The device developed makes
it possible to participate in the therapeutic education of patients
and to improve their quality of life as well as that of healthcare
professionals.
Jean-Frédéric Chibret, President of Théa, said: “We are
very pleased to be able to rely on BIOCORP's expertise in the
development of connected medical devices within different
therapeutic areas in order to develop, in the near future, a new
ecosystem for patients. We see technological innovation as a lever,
which must be used to strengthen the doctor-patient bond. This
agreement is the culmination of several years of working together
to define the contours of a health approach connected to the
ophthalmology department. THEA Laboratories have always been
committed to patients and health professionals. They offer
increasingly innovative technologies to improve the quality of life
of patients.”
Eric Dessertenne, Chief Executive Officer of BIOCORP, added: “We
have been collaborating in confidence with Thea Laboratories for
many years. We are very proud of this new partnership because it
allows us to deploy BIOCORP's two areas of expertise: the
production of innovative and secure products for the pharmaceutical
industry and the design of a connected environment dedicated to
patient compliance. This agreement with Théa represents a very
interesting industrial opportunity and marks our entry into the
ophthalmology market and its associated services.”
ABOUT THÉA
Théa is the leading European pharmaceutical group in
ophthalmology (excluding the retinal market). Based in
Clermont-Ferrand, it has some thirty subsidiaries in Europe, North
and South America, North Africa and the Middle East. Today, its
network includes nearly 1,500 employees, and its products are
available in nearly 70 countries around the world. An independent
and family-owned group, founded from a Research and Development
start-up by Henri CHIBRET, who belongs to the 4th generation of a
dynasty in the world of ophthalmology, Théa has been chaired since
2008 by Jean-Frédéric CHIBRET (5th generation).
http://www.laboratoires-thea.com/fr
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This intelligent sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of diabetics. Available for sale from
2020, Mallya spearheads BIOCORP's product portfolio of innovative
connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
ALCOR).
For more information, please visit
www.biocorpsys.com.
Follow us on Twitter @BIOCORPSystems
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200618005870/en/
THÉA CONTACTS: lorraine.kaltenbach@theapharma.com
BIOCORP CONTACTS Jacques Gardette Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne Chief Executive Officer Sylvaine Dessard
Marketing & Communication Director rp@biocorp.fr + 33 (0)6 88
69 72 85 ULYSSE COMMUNICATION CONTACTS Bruno ARABIAN
barabian@ulysse-communication.com +33 (0)6 87 88 46 26
Nicolas DANIELS ndaniels@ulysse-communication.com +33 (0)6 63 66
59 22
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Apr 2023 a Apr 2024